What happened with MDGL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Madrigal Pharmaceuticals sells Rezdiffra, a once-daily oral medicine for adults with metabolic dysfunction-associated steatohepatitis (MASH) who have moderate to advanced liver scarring but not cirrhosis. Rezdiffra is its only approved product and supplies its product revenue. Most revenue comes from the United States; the company has also launched the drug in Germany.
In the United States, Madrigal sells through a small group of specialty pharmacies that account for nearly all its U.S. revenue. Patient access depends on doctors prescribing the drug and government and private insurers covering its cost. Coverage decisions, rebates and patient out-of-pocket costs affect both demand and how much Madrigal earns from sales.
Madrigal outsources all manufacturing: Evonik supplies the active ingredient, while UPM is its primary U.S. tablet supplier and Corden its primary European tablet supplier. Continued sales also depend on meeting regulatory commitments. Rezdiffra has accelerated approval in the United States and conditional authorization in the European Union, rather than standard full approvals. Confirmatory trials must establish clinical benefit and post-approval obligations must be met; failure could lead to withdrawal of authorization. Its current approved use excludes cirrhosis, and broader uses require additional approvals.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Madrigal’s results hinge on Rezdiffra uptake; Roche, absent from this list, licenses resmetirom to Madrigal and receives royalties while also developing competing Phase 3 MASH treatments.
Novo Nordisk already competes for MASH patients with Madrigal: its semaglutide is FDA-approved, while Madrigal sells oral Rezdiffra. Semaglutide’s use in MASH is the relevant competitive signal, rather than Novo’s broader diabetes business.
Inventiva’s Phase 3 oral lanifibranor could challenge Madrigal’s oral Rezdiffra in the MASH market. Lanifibranor is Inventiva’s only drug candidate in development, making its trial progress the clearest signal to watch.
Viking Therapeutics is developing an oral MASH drug that acts on the same thyroid hormone receptor, THR-β, as Madrigal’s marketed Rezdiffra. Viking has not generated revenue, so its drug-development progress—not product sales—is the signal to watch for this potential rival.
Altimmune’s investigational pemvidutide could compete for MASH patients treated with Madrigal’s Rezdiffra. Watch its MASH trial results for liver effects and tolerability; Altimmune is also developing the drug for other liver-related conditions.
Sagimet Biosciences is developing oral denifanstat for the MASH patients Madrigal treats with Rezdiffra. Denifanstat blocks an enzyme involved in making fatty acids, FASN, offering a different drug mechanism whose development progress matters for Rezdiffra’s competition.
Eli Lilly’s Phase 3 MASH treatments could become competitors to Madrigal’s marketed Rezdiffra. For Madrigal holders, the relevant Lilly news is progress in those MASH programs, rather than sales across its wider medicines business.
GSK’s developing MASH therapy could compete with Madrigal’s Rezdiffra for patients with liver fibrosis, using an FGF-21 approach rather than Rezdiffra’s THR-β mechanism. Its clinical progress in these patients is more relevant to Madrigal than GSK’s broader medicine and vaccine sales.
Pfizer gave Madrigal exclusive global rights to develop, manufacture and sell the Phase 2 oral drug ervogastat and two early-stage MASH assets, in return for upfront payments, potential milestones and sales royalties. Madrigal paid $50 million upfront in December 2025; ervogastat’s progress could trigger further payments to Pfizer before any sales.
Fed Interest Rate Decision
Madrigal’s $350 million loan bears interest at three-month term SOFR, a benchmark borrowing rate, plus 4.75%, so Fed decisions that shift rates can change what the company pays in interest.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, higher benchmark rates can lift interest on Madrigal’s loan and leave less cash for Rezdiffra commercialization and development.
If it comes in below expectations
If the Fed sets rates lower than expected, lower benchmark rates can reduce interest on Madrigal’s loan and leave more cash for Rezdiffra commercialization and development.
Madrigal Pharmaceuticals, Inc. earningsThis company
Madrigal’s report will show whether Rezdiffra sales are growing fast enough to keep pace with the cost of expanding its commercial business.
Read Rezdiffra product revenue alongside the operating loss. Faster revenue growth with a narrower operating loss would show sales are starting to offset the cost of commercialization; slower revenue growth with a still-large loss would show that commercial spending has yet to translate into better operating economics.
Novo-Nordisk A/S earningsNVO
Novo Nordisk’s report will show how semaglutide is progressing in MASH, where it could compete with Madrigal’s Rezdiffra for patients.
Focus on Novo Nordisk’s disclosures about semaglutide in MASH, not its overall diabetes sales. Clear progress would mean patients and doctors have another treatment option alongside Rezdiffra, increasing the potential for competition; limited progress would mean less immediate pressure from this drug.
